Normal view

Received — 26 March 2026 ⏭ Nature Medicine

Nature Medicine
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial Wungki Park · Catherine A. O’Connor · Joanne F. Chou · Marc Hilmi · Zeynep Tarcan · Carly Schwartz · Mary Larsen · Ramzi Homsi · Karthigayini Sivaprakasam · Shigeaki Umeda · Maria A. Perry · Anna M. Varghese · Kenneth H. Yu · Fiyinfolu Balogun · Alice Zervoudakis · Seth S. Katz · Tae-Hyung Kim · Ken Zhao · Allison L. Richards · Nicolas Lecomte · Daniel Martin Muldoon · Elias Karnoub · Walid Chatila · Jessica Yang · Imane El-Dika · Devika Rao · Smita Joshi · Michael B. Foote · Ryan Sugarman · James J. Harding · Andrew S. Epstein · David Kelsen · Sree Chalassani · Fergus Keane · Joshua D. Schoenfeld · Anupriya Singhal · Erin Diguglielmo · Chaitanya Bandlamudi · Junmin Song · Hulya Sahin Ozkan · Junguei Hong · Haochen Zhang · Agustin III Cardenas · Maria Lao · Jerry Melchor · Ronak Shah · Wenfei Kang · Francesca Mazzoni · Kevin Soares · Mark TA Donoghue · Ernesto Santos · Vineet Rolston · Marsha Reyngold · Alice Chia-chi Wei · Murray Tipping · Olca Basturk · Michael Berger · Richard Kihn Do · Mark Schattner · William R. Jarnagin · Nadeem Riaz · Vinod Balachandran · Dana
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.
25 March 2026 at 08:00

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

By: Wungki Park · Catherine A. O’Connor · Joanne F. Chou · Marc Hilmi · Zeynep Tarcan · Carly Schwartz · Mary Larsen · Ramzi Homsi · Karthigayini Sivaprakasam · Shigeaki Umeda · Maria A. Perry · Anna M. Varghese · Kenneth H. Yu · Fiyinfolu Balogun · Alice Zervoudakis · Seth S. Katz · Tae-Hyung Kim · Ken Zhao · Allison L. Richards · Nicolas Lecomte · Daniel Martin Muldoon · Elias Karnoub · Walid Chatila · Jessica Yang · Imane El-Dika · Devika Rao · Smita Joshi · Michael B. Foote · Ryan Sugarman · James J. Harding · Andrew S. Epstein · David Kelsen · Sree Chalassani · Fergus Keane · Joshua D. Schoenfeld · Anupriya Singhal · Erin Diguglielmo · Chaitanya Bandlamudi · Junmin Song · Hulya Sahin Ozkan · Junguei Hong · Haochen Zhang · Agustin III Cardenas · Maria Lao · Jerry Melchor · Ronak Shah · Wenfei Kang · Francesca Mazzoni · Kevin Soares · Mark TA Donoghue · Ernesto Santos · Vineet Rolston · Marsha Reyngold · Alice Chia-chi Wei · Murray Tipping · Olca Basturk · Michael Berger · Richard Kihn Do · Mark Schattner · William R. Jarnagin · Nadeem Riaz · Vinod Balachandran · Dana

25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5

Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.

Nature Medicine
<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial Omar S. Mabrouk · Ben Tichler · H. Moore Arnold · Eva C. Thoma · Sara M. Alexanian · Jingxian Chen · Tzu-Ying Liu · Beth Hirschhorn · Roy Llorens Arenas · John W. Annand · Unnati Kapadnis · Alan A. Shomo · Kelly E. Glajch · Kyle Ferber · Yuka Moroishi · Julie Czerkowicz · Jennifer Inra · Ronald B. Postuma · Tanya Gurevich · Pablo Mir · Huw R. Morris · Jason Aldred · Matthew A. Brodsky · Aaron Ellenbogen · Danielle Larson · Christopher M. Tolleson · Andrew Siderowf · Charalampos Tzoulis · Ernest Balaguer · Maria J. Marti · Hien T. Zhao · Holly B. Kordasiewicz · Roger Lane · Warren D. Hirst · Stephanie Fradette · Danielle L. Graham
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.
24 March 2026 at 08:00

<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

Nature Medicine

By: Omar S. Mabrouk · Ben Tichler · H. Moore Arnold · Eva C. Thoma · Sara M. Alexanian · Jingxian Chen · Tzu-Ying Liu · Beth Hirschhorn · Roy Llorens Arenas · John W. Annand · Unnati Kapadnis · Alan A. Shomo · Kelly E. Glajch · Kyle Ferber · Yuka Moroishi · Julie Czerkowicz · Jennifer Inra · Ronald B. Postuma · Tanya Gurevich · Pablo Mir · Huw R. Morris · Jason Aldred · Matthew A. Brodsky · Aaron Ellenbogen · Danielle Larson · Christopher M. Tolleson · Andrew Siderowf · Charalampos Tzoulis · Ernest Balaguer · Maria J. Marti · Hien T. Zhao · Holly B. Kordasiewicz · Roger Lane · Warren D. Hirst · Stephanie Fradette · Danielle L. Graham

24 March 2026 at 08:00

Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4

The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.